Genelux Corporation Appoints Jodi Devlin as President

SAN DIEGO, Jan. 12, 2011 /PRNewswire/ -- Genelux Corporation, a privately held, San Diego-based biopharmaceutical company developing novel therapies against cancer, today announced that its Board of Directors has appointed Jodi Devlin as the company's President effective January 10, 2011.  Dr. Aladar Szalay, the company's Founder, will continue to serve as CEO and Chairman of the Board.

"Ms. Devlin is an excellent choice to lead Genelux Corporation into the next phase of growth, from commercializing the Company's leading cancer therapy to transforming the Company's operations accordingly," said Dr. Aladar Szalay, Founder, Chairman and CEO.  "She brings two decades of extensive commercialization and executive management experience at one of the world's leading pharmaceutical companies to Genelux and has the vision and energy to help us realize our goals."

Ms. Devlin's experience spans a broad range of functions including commercialization, clinical development, strategic business development and planning.  Most recently, Ms. Devlin served as Vice President at Abbott where she led Global Pipeline Marketing for all therapeutic areas, including oncology.  Over the course of her career, Ms. Devlin held positions as Vice President of International Marketing, U.S. Specialty Operations, Primary Care and Virology.  Under her leadership, HUMIRA®, Kaletra® and TriCor® all achieved multi-billion dollar status.  Ms. Devlin holds a BS in Nursing from the University of Oklahoma and an MBA from Washington University Olin School of Business.

"We are very pleased that Ms. Devlin will be joining our team at an exciting time in the company's evolution," said Dr. Szalay. "Her proven leadership and management capabilities have prepared her well for this new challenge.  She is a competent professional and knows how to bring a product successfully to market.  We believe she has the right combination of experience, results-orientation and talent to grow and build Genelux Corporation. "

"Having served on the search committee, I had the opportunity to evaluate a number of strong candidates.  Ms. Devlin stood out as our top choice," said Dr. Albert Roeder, COO and a member of the company's Board of Directors. "Her skill set richly complements our current capabilities and strengthens our future commercialization plans."

"It is an honor to join Genelux Corporation as the company's first President," said Ms. Devlin. "I am excited to help bring such innovative and potentially life-saving technology to cancer patients and to rapidly advance the company's tremendous portfolio of therapeutics and diagnostics.  I look forward to working with Dr. Szalay, the Board of Directors, and our management team for the benefit of cancer patients while generating value for our shareholders.  In addition, I will continue to build upon the positive and rewarding environment for our employees."

About Genelux Corporation

Genelux Corporation was founded in 2001 with a mission to develop safe and effective diagnostic and therapeutic solutions for cancer and inflammatory diseases for which there are no effective treatments today. Genelux Corporation is headquartered in San Diego, California,

Genelux Forward Looking Statement

Statements made about Genelux Corporation, other than statements of historical fact, reflect Management's current beliefs and assumptions founded on the data and information currently available to us. Statements of the company's progress, results, timing of pre-clinical and clinical trials and projections for product pipelines are examples of forward-looking statements. By definition, such undertakings involve risks, uncertainties and assumptions, and are subject to a number of such factors that could cause actual results to differ substantially from statements made, including but not limited to: risks associated with the success of clinical trials, research and development programs, regulatory approval processes for clinical trials, competitive technologies and products, patents, inception and/or continuation of corporate and other strategic partnerships and the need for additional funding or financing.  

SOURCE Genelux Corporation